These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34815421)

  • 21. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
    Nygart VA; Pommerencke LM; Haijen E; Kettner H; Kaelen M; Mortensen EL; Nutt DJ; Carhart-Harris RL; Erritzoe D
    J Psychopharmacol; 2022 Aug; 36(8):932-942. PubMed ID: 35924888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
    Kuc J; Kettner H; Rosas F; Erritzoe D; Haijen E; Kaelen M; Nutt D; Carhart-Harris RL
    Psychopharmacology (Berl); 2022 May; 239(5):1425-1440. PubMed ID: 34734314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowing and being known: Psychedelic-assisted psychotherapy and the sense of authenticity.
    Fischman LG
    Front Psychiatry; 2022; 13():933495. PubMed ID: 36203843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.
    Kious B; Schwartz Z; Lewis B
    J Psychopharmacol; 2023 Jan; 37(1):45-48. PubMed ID: 36377548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An introduction to psychedelic neuroscience.
    Calvey T; Howells FM
    Prog Brain Res; 2018; 242():1-23. PubMed ID: 30471677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychedelic Drugs in Biomedicine.
    Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV
    Trends Pharmacol Sci; 2017 Nov; 38(11):992-1005. PubMed ID: 28947075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 30. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder.
    Spriggs MJ; Kettner H; Carhart-Harris RL
    Eat Weight Disord; 2021 May; 26(4):1265-1270. PubMed ID: 32895801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives.
    Rankaduwa S; Owen AM
    Neurosci Conscious; 2023; 2023(1):niad001. PubMed ID: 37025356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI).
    Nour MM; Evans L; Nutt D; Carhart-Harris RL
    Front Hum Neurosci; 2016; 10():269. PubMed ID: 27378878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenomenology, Structure, and Dynamic of Psychedelic States.
    Preller KH; Vollenweider FX
    Curr Top Behav Neurosci; 2018; 36():221-256. PubMed ID: 28025814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychedelics and disorders of consciousness: the current landscape and the path forward.
    Cardone P; Alnagger N; Annen J; Bicego A; Gosseries O; Martial C
    Neurosci Conscious; 2024; 2024(1):niae025. PubMed ID: 38881630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.
    Yaden DB; Johnson MW; Griffiths RR; Doss MK; Garcia-Romeu A; Nayak S; Gukasyan N; Mathur BN; Barrett FS
    Int J Neuropsychopharmacol; 2021 Aug; 24(8):615-623. PubMed ID: 33987652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.
    Holoyda B
    Psychiatr Serv; 2020 Dec; 71(12):1297-1299. PubMed ID: 33050796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.
    Argento E; Socias ME; Hayashi K; Choi J; Mackay L; Christie D; Milloy MJ; DeBeck K
    Int J Drug Policy; 2022 Feb; 100():103518. PubMed ID: 34758431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture.
    Hartogsohn I
    Transcult Psychiatry; 2022 Oct; 59(5):579-591. PubMed ID: 35818775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.
    Raison CL; Jain R; Penn AD; Cole SP; Jain S
    Front Psychiatry; 2022; 13():831092. PubMed ID: 35370864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.